Ph.D., VP & Head of Personalised Healthcare & Biomarkers, AstraZeneca
Ruth March, VP and Head of Personalised Healthcare and Biomarkers, leads AstraZeneca’s function of world class diagnostic and biomarker science experts, delivering companion diagnostic tests to target AZ drugs to the right patients across each therapy area and all phases of development. She has driven adoption of Personalised Healthcare approaches by 70% of AstraZeneca’s pipeline, partnering with a strategic network of diagnostic companies to ensure delivery to global clinical trials and marketed products.
Ruth spent ten years in immunology and genetics research at the Universities of London and Oxford. She has over 40 publications and patents in the field of pharmacogenomics and Personalised Healthcare and serves as an expert evaluator for the European Commission.
Personalised Healthcare in Metabolic Disease
The use of diagnostics and biomarkers to target treatments to patients most likely to benefit can benefit industry, physicians and patients. In metabolic and related diseases, diagnostics may help to stratify disease and track response to therapy. Next generation sequencing may also transform the discovery of new biomarkers and targets.